↓ Skip to main content

Dove Medical Press

Article Metrics

Hypercalcemia of malignancy and new treatment options

Overview of attention for article published in Therapeutics and Clinical Risk Management, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 1,108)
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
1 news outlet
twitter
14 tweeters
facebook
1 Facebook page
video
1 video uploader

Citations

dimensions_citation
92 Dimensions

Readers on

mendeley
144 Mendeley
Title
Hypercalcemia of malignancy and new treatment options
Published in
Therapeutics and Clinical Risk Management, December 2015
DOI 10.2147/tcrm.s83681
Pubmed ID
Authors

Ilya G. Glezerman, Hillel Sternlicht

Abstract

Hypercalcemia of malignancy affects up to one in five cancer patients during the course of their disease. It is associated with both liquid malignancies, commonly multiple myeloma, leukemia, and non-Hodgkins lymphoma and solid cancers, particularly breast and renal carcinomas as well as squamous cell carcinomas of any organ. The clinical manifestations of hypercalcemia are generally constitutional in nature and not specific to the inciting malignancy. Such physical manifestations can range from malaise to lethargy and confusion. Constipation and anorexia are common. Acute kidney injury is likely the most frequently encountered manifestation of end organ damage. Symptomatology is closely linked to both the absolute elevation of serum calcium levels and the rapidity of calcium rise. The majority of cases are humoral in etiology and related to parathyroid hormone-related protein (PTHrP). Approximately 20% of cases are the result of direct bone metastasis with extra-renal 1,25-dihydroxyvitamin D (calcitriol) and ectopic parathyroid hormone production likely accounting for less than 1% of cases. The diagnosis of hypercalcemia of malignancy is confirmed either by an elevated PTHrP or by an evidence of bone metastasis in the appropriate clinical setting. Treatment is predicated on the patient's symptoms and absolute serum calcium level. Interventions are aimed at lowering the serum calcium concentration by inhibiting bone resorption and increasing urinary calcium excretion, the former accomplished via bisphosphonate therapy and the latter with aggressive hydration. Novel therapies for refractory disease include denosumab, a monoclonal antibody against the receptor activator of nuclear factor κB ligand, and the calcimimetic cinacalcet. Finally, anti-PTHrP antibodies have been successfully deployed in animal models of disease. Despite the efficacy of the above therapies, hypercalcemia of malignancy portends an ominous prognosis, indicating advanced and often refractory cancer with survival on the order of months.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 <1%
Brazil 1 <1%
Unknown 142 99%

Demographic breakdown

Readers by professional status Count As %
Other 26 18%
Student > Postgraduate 18 13%
Student > Bachelor 18 13%
Student > Master 17 12%
Student > Ph. D. Student 11 8%
Other 29 20%
Unknown 25 17%
Readers by discipline Count As %
Medicine and Dentistry 78 54%
Nursing and Health Professions 11 8%
Biochemistry, Genetics and Molecular Biology 6 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Agricultural and Biological Sciences 4 3%
Other 5 3%
Unknown 36 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2020.
All research outputs
#1,337,767
of 17,786,057 outputs
Outputs from Therapeutics and Clinical Risk Management
#48
of 1,108 outputs
Outputs of similar age
#32,240
of 375,179 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 49 outputs
Altmetric has tracked 17,786,057 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,108 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 375,179 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.